Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • BioArtic

    - PMLiVE

    Lilly and Indiana University collaborate to expand clinical trial access

    The five-year agreement includes a focus on R&D for Alzheimer’s disease

    - PMLiVE

    Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

    While the trials did not meet their primary endpoints, they highlighted important biomarker findings

    - PMLiVE

    Vandria announces positive phase 1 data for Alzheimer’s treatment

    Trial data showed that VNA-318 has the ability to penetrate the brain

    - PMLiVE

    Eisai submits new drug application for subcutaneous Leqembi in Japan

    LEQEMBI is a treatment for early Alzheimer’s disease

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    - PMLiVE

    Lilly’s early Alzheimer’s disease treatment approved in the EU

    Marketing authorisation follows positive late-stage trial results

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

    An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

    - PMLiVE

    Eli Lilly’s Alzheimer’s disease drug donanemab recommended by CHMP

    Up to 6.9 million people in Europe are affected by the neurodegenerative disorder

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s disease drug Leqembi granted EC approval

    The neurodegenerative disorder currently affects an estimated 6.9 million people in Europe

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug approved by FDA for monthly maintenance dosing

    The neurodegenerative disease affects almost seven million people in the US

    Biogen Idec building

    Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug

    The injection process for subcutaneous Leqembi is expected to take an average of 15 seconds

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug lecanemab receives CHMP recommendation

    The neurodegenerative disorder affects an estimated 6.9 million people in Europe

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links